SUDA Reports Key Developments During Third Quarter FY 2020

April 30, 2020 01:07 PM AEST
Team Kalkine

Oro-mucosal drug delivery company, SUDA Pharmaceuticals Limited (ASX:SUD) released its quarterly report for the three-month period ended 31^st March 2020. The Company highlighted the following key developments for the March quarter:

Commencement of Dr Michael Baker’s role as SUDA’s CEO.
Appointment of General Manager for Perth operations.
Signing of a new licence pact with MTPK (Mitsubishi Tanabe Pharma Korea Ltd) pertaining to ZolpiMist.
Kicking off feasibility studies with Ordesa and Sanofi.

The Company’s cash receipts stood at $323,000 for the quarter, with a bank balance of $1,508,000 at 31^st March 2020.

As at 12:07 PM AEST on 30^th April 2020, SUD is trading at $0.049 with a rise of ~2.1 per cent.

Disclaimer

The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.